WEST PHARMACEUTICAL SERVICES INC
Company Stats
- Market Cap
- $26.1B
- as of Sep 30, 2026
- Enterprise Value
- $25.5B
- Shares Outstanding
- 69.7M
- Free Float
- 92.7%
Income Statement
- Revenue
- $3.1B
- Operating Income
- $584.9M
- Net Income
- $493.7M
- EBITDA
- $756.3M
- Non-cash Impairment
- $11.7M
- Revenue Growth, 3Y
- 2.1%
- FCF Margin, 3Y Avg
- 13.0%
- FCF Margin, Worst Year
- 9.6%
Cash Flow
- Free Cash Flow
- $468.9M
- FCF Yield
- 1.8%
- Owner FCF Yield
- 1.7%
Balance Sheet
- Cash & Equivalents
- $791.3M
- Total Debt
- $203.0M
- Net Cash
- $588.3M
- EV / EBITDA
- 33.72x
Returns & Capital
- Dividends Paid
- $61.2M
- Dividend Yield
- 0.2%
- Dividend Payout, 3Y Avg
- 11.3%
- Share Repurchases
- $134.0M
- Buyback Yield, 3Y Avg
- 1.4%
- SBC, 3Y Avg
- $21.9M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $3.1B | $468.9M | 15.3% |
| FY2024 | $2.9B | $276.4M | 9.6% |
| FY2023 | $2.9B | $414.5M | 14.1% |
| FY2022 | $2.9B | $439.4M | 15.2% |
| FY2021 | $2.8B | $330.6M | 11.7% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 7, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back